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Table 1. Baseline patient characterisitcs
Patient Characteristics
TCD group
(n595)
Non-TCD
group (n555)
Sex: n (%)
Men 60 (63) 34 (62)
Women 35 (37) 21 (38)
Age: median (range) 50 (17-69) 48 (20-63)
Diagnosis: n (%)
Acute Leukemia/MDS 53 (56) 35 (64)
Non-Hodgkin Lymphoma 23 (24) 4 (7)
Chronic Leukemia 9 (9) 14 (25)
Others 10(11) 2 (4)
Conditioning regimen: n (%)
Myeloablative 69 (72.6) 45 (81.8)
Reduced intensity / non-myeloablative 26 (27.4) 10 (18.2)
Risk group: n (%)
Standard risk 13 (14) 21 (38)
High risk 82 (86) 34 (62)
Donor type: n (%)
Sibling 36 (37.9) 39 (70.9)
Unrelated 59 (62.1) 16 (29.1)
HLA mismatch: n (%) 13 (13.7%) 4 (7.3%)
CD 34+ dose: median (range) x
10*6/Kg body wt.
6.2 (1.9-16) 5.4 (1.2-12.9)
S310 Poster Session II(28.9% v 50%; p5 0.06), URD (48.3% v 64.7%; p5 0.23) andHLA
mismatched AHCT (p5 0.59), were not significantly different. The
incidence of chronic GVHD in the TCD and non-TCD groups was
41.1% (n 5 39) and 45.5% (n 5 25) respectively (p0.86). On sub-
group analysis of patients undergoing matched sibling, URD and
HLA-mismatched AHCT, no significant difference in rates of
cGVHD between the two groups was seen (p . 0.05). Relapse rates
in the TCD and non-TCD groups were 32.6% and 40% (p 5 0.22)
respectively. The overall survival at 3years was 39.2% in the TCD
group and 39.3% in the non-TCD group; p5 0.93. The 3year pro-
gression free survival in similar order were 34.8% and 27.2% respec-
tively (p5 0.85). Non relapse mortality at day 100 respectively were
12.8% and 16% and at 3years were 40% and 41% (p . 0.05).
Our limited, single institution experience in a cohort of 150 con-
secutive patients suggest no significant benefit with routine use of in
vivo TCD with AHCT. These results highlight the need to develop
novel strategies for preventing GVHD and for improving transplan-
tation outcomes.430
OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
FOR WISKOTT ALDRICH SYNDROME
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Human leukocyte antigen (HLA) identical sibling donor trans-
plantation remains the treatment of choice forWiskott Aldrich Syn-
drome (WAS), however, utilization of alternative donor sources has
significantly increased since 1990. We report the hematopoietic cell
transplantation (HCT) outcomes of 47 patients withWAS treated at
a single center since 1990 with significant improvement in outcomes
after 2000 despite the increased use of alternative donors. 5 year
overall survival (OS) improved from 62.5% (95% CI: 34.9% to
81.1%) to 90.8% (95% CI: 67.7% to 97.6%) for patients trans-
planted during 1990-2000 and 2001-2009, respectively. When
adjusted for age at HCT, OS was significantly higher in the 2001-
2009 era (p 5 0.04, Cox proportional hazard analysis). No early
transplant related mortality (within the first 100 days) occurred
among patients transplanted during 2001-2009 compared to 3/16
during 1990-2000, (p 5 0.03, Fisher’s exact test). The extent of
HLA mismatch did not significantly affect the incidence of acuteGVHD, chronic GVHD, or survival. Post-HCT autoimmune cyto-
penias were frequently diagnosed after 2001: 17/31 (55%) patients.
Their occurrence was not associated with transplant donor type
(p 5 0.53), or occurrence of acute GVHD (p 5 0.74), chronic
GVHD (p 5 0.12), or mixed chimerism (p 5 0.50).431
ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC ACTIVE EBV
INFECTION (CAEBV)
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Chronic active Epstein Barr virus infection (CAEBV) encom-
passes a variety of EBV-associated lymphoproliferative diseases
(LPD) in the non-immunocompromised host. In CAEBV either B,
T, and/or NK cells are primarily infected with EBV and patients
present with a variety of clinical signs and symptoms including fever,
hepatosplenomegaly, and lymphadenopathy. While rare in the
Western hemisphere, T and NK cell CAEBV is most commonly
seen in Japan. In Japan, current treatment protocols rely on chemo-
therapy and hematopoietic stem cell transplantation (HSCT).
To evaluate the clinical outcome of HSCT in CAEBV patients in
the United States, we reviewed our experience with 6 CAEBV pa-
tients (4 T-cell, 1 NK-cell, 1 B-cell), who underwent allogeneic
HSCT for their disease. Median age at transplant was 11 yrs (range
6 – 25 yrs) and the median time to transplant from diagnosis was 3.7
years (range 4.3 yrs – 8.5 yrs). Four of 6 patients had persistent or re-
fractory disease at the time ofHSCT. Four patients receivedmyeloa-
blative conditioning while 2 patients received reduced intensity
conditioning (RIC). Median time to neutrophil engraftment was
16 days (range days 11 – 21 days) with no long-term engraftment fail-
ure. Five patients received infusions of donor derived EBV-specific
cytotoxic T cells (CTLs) at a median of 6 months (range 2.5 months
– 12 months) post HSCT. Five patients are alive and in complete re-
mission with a median survival of 2.5 yrs (range 7 months – 10 yrs).
One patient developed recurrent T-cell CAEBV immediately post
transplant and died of an aggressive T-cell lymphoma 3.7 years
post transplant.
Our results support published data from Japan showing good out-
comes for CAEBV patients after allogeneic HSCT. Factors that may
influence outcome and warrant further study include the timing of
transplantation after diagnosis and the use of EBV-directed T-cell
therapies.432
HAPLOIDENTICAL STEM CELL TRANSPLANTS IN CHILDRENWITH ACUTE
LYMPHOBLASTIC LEUKEMIA IN FIRST OR SECOND REMISSION
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Allogeneic hematopoietic stem cell transplant (SCT) offers cura-
tive therapy to children with high-risk or relapsed acute lymphoblas-
tic leukemia (ALL). Here, we report encouraging results using
haploidentical related donor CD34+ selected (T-cell depleted) pe-
ripheral blood stem cell transplants in children with ALL in first
or second remission (CR1 or CR2). From May 2002 to September
2009, we transplanted 17 children (13 male, 4 female) in CR1 (n 5
6) and CR2 (n5 11) using primarily a fully myeloablative condition-
ing regimen consisting of cyclophosphamide 45mg/kg x 2 doses, cy-
tarabine arabinoside 3gm/m2 x 6 doses and total body irradiation
(TBI) 1400cGy (n5 12). Five patients received either a reduced-in-
tensity regimen or busulfan-based regimen for clinical purposes
(such as to avoid TBI exposure). All patients received alemtuzumab
(3, 5 or 10mg/dose depending on body weight) during conditioning
for in vivo T-cell depletion to promote engraftment and provide ad-
ditional GvHD protection. If the infused T-cell dose was less than
Poster Session II S3115x104 CD3 cells/kg, no additional GvHD prophylaxis was adminis-
tered. The median age at transplant was 9.9 years (range, 2.9 to 21.6)
and median follow-up 44 months post SCT (range, 13 to 102). Me-
dian CD34+ cell dose infused was 1.14x107/kg (range, 0.49-
6.83x107/kg) and median CD3+ T-cell dose was 3.08x104/kg (range,
1.8x104-1.6x105/kg). The rate of donor engraftment was 82.4% – 3
patients failed to achieve initial donor engraftment but did so after
receiving subsequent haploidentical SCT. Eleven of 17 (65%) pa-
tients received additional T-cell therapies post SCT (donor lympho-
cytes for mixed chimerism, cytotoxic T-lymphocyte therapy or
planned T-cell addback strategies to re-establish T-cell immune re-
constitution) and 2 received additional CD34+ cells for poor graft
function. Two-year disease-free survival for these children is
60.5%. Of the 5 children who died, 2 died of relapse and 3 of treat-
ment-related causes, primarily infection. One patient with p53 mu-
tation developed secondary MDS 2 years post SCT and is alive
with disease. In conclusion, while this data is preliminary, haploi-
dentical transplants using in vivoT-cell depletion with alemtuzumab
and ex vivo T-cell depletion with CD34+ selection offers promising
clinical results in children with ALL in CR1 or CR2.With the addi-
tion of new clinical immunotherapy trials post SCT, we hope to
achieve even higher survival with decreased relapse and deaths
related to viral infection.433
LEUKEMIA RELAPSE: DETECTED BY BONE MARROW CHIMERISM ANAL-
YSIS BUT MISSED BY PERIPHERAL BLOOD ENGRAFTMENT MONITORING
ALONE
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Chimerism analysis is frequently used for the surveillance of en-
graftment especially post allogenic stem cell transplantation for ma-
lignant hematopoietic diseases (HSCT). The most common
method, PCR-based short tandem repeats (STR) analysis, offers
high sensitivity and specificity in monitoring graft chimerism after
HSCT. Multiple panels of STRs have been developed for use on
bone marrow aspirate (BMA) and peripheral blood (PB). In accor-
dance with 2001workshop (tandemmeeting ASBMT) recommenda-
tions, PB has been widely used to serially characterize the
hematologic course of engraftment and/or occurrence. In the pres-
ent study, we evaluated the value of STR assay for surveillance of
acute leukemia relapse in patients with established HSCT engraft-
ments. A total of 87HSCT recipients with clinically stable and estab-
lished engraftment were retrospectively analyzed. All cases had been
monitored by serial STR analysis using both BMA and PB samples
with a commercially available panel of ten markers (D3S1358-
vWA-FGA-AMEL-D8S1179-D21S11-D18S51-D5S818-D13S317-
D7S820). Additionally, patients’ bone marrow biopsies were also
reviewed at the time of BMA STR analysis. Among these 87 patients,
70 patients sustained complete remission and their PB and BMA
showed 100% donor origin in the STR assays. There were 17 pa-
tients who had relapse ranging from 81 days to 442 days after trans-
plantation, as documented by BM biopsy and/or clinical
presentation. All of these 17 patients showed a mixed chimerism
on BMA STR assay at the same time BM biopsy showed relapse.
In these relapse patients, the percentage of donor origin were lower
in granulocytes than in mononuclear cells (52.468% vs 84.564%; p
\ 0.05) while 3 patients showed mixed chimerism in the mononu-
clear cells only. In contrast, there were 4 out of the 17 patients
with negative PB STR assays in the immediate time period around
which the BMA STR analysis became positive. Interestingly, in
one patient when BM STR assay showed mixed chimerism, the
BM biopsy obtained at the same time was inconclusive for relapse.
Our findings indicated that caution should be taken when using
PB STR solely to monitor leukemia relapse because it maymiss early
recurrence. This may delay a change in treatment. Second, BM STR
assay is a very sensitive method in HSCT surveillance even in pa-
tients with a negative or inconclusive BM biopsy. At last, mononu-
clear cells are more sensitive in detecting mixed chimerism than
granulocytes.434
FACILE DOUBLE CORD TRANSPLANT SCREENING AND MONITORING
Bost, D.A., McLaughlin, I.J., Beckert, S. Celera, Alameda, CA
STR-PCR is limited in its utility for screening and monitoring of
donors and recipients in double cord transplants, given its inherent
lack of sensitivity and the presence of stutter artifacts which obscure
potentially informative alleles. If markers are identified for each in-
dividual in a double cord transplant, the manual execution of the al-
gorithm for quantification of individuals is quite time-consuming.
To simplify these analyses, we designed a multiplexed system of
RUO assays and software enabling instantaneous marker identifica-
tion and quantification post-PCR.
We employ a panel of 34 quantitative PCR research assays to bi-
allelic indels in which the probability of finding at least one informa-
tive marker is. 99.9% in unrelated individuals (Caucasian, African,
Japanese, Amerindian populations). The probability of finding at
least one informative marker in siblings is . 99%, 98%, 98% and
97% for European Caucasian, Japanese, Amerindian and African
populations, respectively.
Results: Each research assay was tested using simulated DNA mix-
tures at 0.05%, 0.1%, 0.2% and 0.4% minor component for 250 ng
of input genomic DNA. Each assay detected the 0.05% minor com-
ponent mixture. The limitation at this low sensitivity is input copy
number. In addition, each of the assays in the panel was able to de-
tect, with statistical significance (p\ 0.05), the 2-fold change be-
tween the 0.1% and 0.2% minor component mixtures. Multiple
assays tested on the same mixtures gave highly reproducible results.
We also developed research use software allowing for facile analysis
of marker screening and post-transplant monitoring quantification.
Results are generated with one click of a mouse button.
Conclusions: Use of this research qPCR system for screening and
engraftment monitoring of double cord transplants would enable
rapid identification of informative markers and several logs increase
in sensitivity over the current standard practices. The ability to de-
tect early changes in increasing mixed chimerism, with greater accu-
racy and precision, allows for more effective research into the
potential benefits of earlier detection of clinically significant events,
such as relapse or rejection.435
ATTEMPTS TO OPTIMIZING THE OUTCOMES OF ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION IN OLDER PATIENTS ($60 YEARS)
WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
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Using a non-myeloablative (NMA) regimen [Fludarabine 125mg/
m2 and total body irradiation (TBI) 200cGY], we previously reported
the feasibility of allogeneic hematopoietic cell transplantation
(HCT) in older patients (n 5 24) with AML/MDS using matched
sibling donors (MSD) (Gupta et al, 2005, BBMT). GvHD prophy-
laxis was with Cyclosporine (CsA) (42 days) and Mycophenolate
(MMF) for (30 days); CsA was tapered at 42 days in the absence of
GvHD.While survival was reasonable; 2 main issues were identified:
early relapse and severe chronic GvHD in some patients. To address
these issues, we added IV Busulphan (3.2mg/KBWIV daily x 2 days)
to Flu/TBI regimen, and increased the duration of GvHD prophy-
laxis with CsA from 42 days to 100 days. We compare the outcomes
of these 2 sequential strategies: Cohort 1 (n 5 24, treated 2000-
2004), less intense NMA regimen and shorter GvHD prophylaxis;
Cohort 2 (n 5 31, treated 2005-2009), more intense NMA regimen
and longer GvHD prophylaxis. The median age of all study patients
(n5 55) was 63 years (range 60-71); 47 (86%) had AML in CR1 (n5
33) or CR2 (n5 14), and 8 (14%) hadMDS; 22% had severe comor-
bidities; and 29% had adverse risk cytogenetics. Baseline character-
istics were well-matched in the two cohorts, except cohort 2 had 6
(19%) patients with unrelated donors HCT. Median follow-up of
survivors in cohort 1 and 2 was 72 months (13-102) and 31 months
(16-49), respectively. A significantly higher proportion of patients
had grade $ 2 stomatitis (Bearman Criteria) in the later cohort
